When both processes occur simultaneously, they may lead to poorer clinical outcomes in GBM patients, which may be related to the related cell cycle dysregulation caused by the simultaneous dysregulation of the EGFR and p53 pathways.19 This evidence concerns the gene TP53 and glioblastoma.